BeOne Medicines (NASDAQ: ONC) insider transactions

In the twelve months to 10 November 2026, executives and directors of BeOne Medicines reported 219 open-market sales of 1,212,576 shares ($392.4m) and 0 open-market purchases, by 12 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in BeOne Medicines shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
6 November 2026	Ball Titus B.	Principal Accounting Officer	Option exercise	+880	$207.55	880	Form 4
6 November 2026	Ball Titus B.	Principal Accounting Officer	Option exercise	+679	$159.03	1,559	Form 4
6 November 2026	Ball Titus B.	Principal Accounting Officer	Open-market sale	−1,533	$405.55	26	Form 4
6 November 2026	Ball Titus B.	Principal Accounting Officer	Open-market sale	−26	$406.34	0	Form 4
5 November 2026	Lee Chan Henry	SVP, General Counsel	Open-market sale, 10b5-1 plan	−660	$400.00	455	Form 4
5 November 2026	Lee Chan Henry	SVP, General Counsel	Open-market sale, 10b5-1 plan	−455	$402.00	0	Form 4
27 October 2026	Wang Xiaodong	Director	Option exercise, 10b5-1 plan	+31,028	$36.90	31,028	Form 4
27 October 2026	Wang Xiaodong	Director	Open-market sale, 10b5-1 plan	−880	$355.56	30,148	Form 4
27 October 2026	Wang Xiaodong	Director	Open-market sale, 10b5-1 plan	−3,965	$365.43	6,903	Form 4
27 October 2026	Wang Xiaodong	Director	Open-market sale, 10b5-1 plan	−6,903	$366.22	0	Form 4
27 October 2026	Wang Xiaodong	Director	Open-market sale, 10b5-1 plan	−1,440	$355.62	28,708	Form 4
27 October 2026	Wang Xiaodong	Director	Open-market sale, 10b5-1 plan	−1,239	$357.54	27,469	Form 4
27 October 2026	Wang Xiaodong	Director	Open-market sale, 10b5-1 plan	−1,681	$358.75	25,788	Form 4
27 October 2026	Wang Xiaodong	Director	Open-market sale, 10b5-1 plan	−1,280	$359.72	24,508	Form 4
27 October 2026	Wang Xiaodong	Director	Open-market sale, 10b5-1 plan	−320	$360.64	24,188	Form 4
27 October 2026	Wang Xiaodong	Director	Open-market sale, 10b5-1 plan	−2,331	$362.35	21,857	Form 4
27 October 2026	Wang Xiaodong	Director	Open-market sale, 10b5-1 plan	−8,148	$363.24	13,709	Form 4
27 October 2026	Wang Xiaodong	Director	Open-market sale, 10b5-1 plan	−2,841	$363.95	10,868	Form 4
13 October 2026	Wang Xiaodong	Director	Option exercise, 10b5-1 plan	+31,027	$36.90	31,027	Form 4
13 October 2026	Wang Xiaodong	Director	Open-market sale, 10b5-1 plan	−7,167	$349.56	23,860	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the BeOne Medicines page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.